The Gastrointestinal Market Outlook to 2012
As the Gastrointestinal Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn's disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs.
The Gastrointestinal Market Outlook to 2012 provides a detailed epidemiological analysis of key indications within major Gastrointestinal markets, and examines the factors impacting their prevalence. The dynamics of the market are examined through an analysis of leading brands within each indication and a profile of the pharma companies and market trends influencing the sales of Gastrointestinal treatments. Forecasts for major product sales over the 2006-12 period are also provided.
Table of Contents
Download Table of Contents as a PDF
Other users found this report page using the following search terms: gastrointestinal GERD ulcer Crohn’s disease ulcerative colitis IBD inflammatory bowel disease irritable bowel syndrome IBS
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.